Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Recursion Pharmaceuticals Inc — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $17.8, while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QYLD | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $18.52 | $6.79 |
52-Week Low | $16.46 | $2.84 |
Market Cap | — | $1.63B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $17.66, down 0.84% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with RSI at oversold levels. Recent dividend payments of $0.18-$0.19 highlight its income focus, though news articles question long-term wealth erosion versus Nasdaq growth.
The outlook remains cautious due to covered-call strategy limitations during market rallies. Risks include NAV erosion and underperformance versus benchmarks. Income-focused investors may find value, but growth-oriented investors face significant upside capture constraints in bullish markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
